MeiraGTx Reports Full Year 2019 Financial Results

March 11, 2020

LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 2019 and provided an update on recent progress.

“During 2019, the MeiraGTx team reached meaningful milestones, including the initiation of two new clinical trials and our entry into a collaboration with Janssen to develop and commercialize our pipeline of inherited retinal disease treatments,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “We have treated patients across five gene therapy clinical trials in the last year and remain committed to developing cutting-edge science that we can translate into treatments for patients affected by severe diseases. Over the next year, we expect to move inherited retinal disease programs into late-stage studies, share preliminary data from our xerostomia program and file an IND to initiate the next clinical study of AAV-GAD for Parkinson’s disease.”

As of December 31, 2019, MeiraGTx had cash and cash equivalents of approximately $227.4 million. The Company believes this capital will be sufficient to fund operating expenses and capital expenditure requirements into 2022.

Recent Clinical Development Highlights and Anticipated 2020 Milestones

AAV-AQP1 for the treatment of Grade 2/3 Radiation-Induced Xerostomia:  

  • MeiraGTx continues to activate clinical trial sites in the Company’s recently initiated Phase 1/2 AQUAx study, with patients now being enrolled at three of five expected study sites. Dosing in the first cohort was completed in the first quarter of 2020.
  • The Company’s single center Phase 1 dose-finding study of AAV-AQP1 also continues to enroll patients at the National Institutes of Health (NIH). Enrollment in the fourth dose escalation cohort is now ongoing.
  • MeiraGTx expects to report preliminary data from the AQUAx clinical trial in the second half of 2020.

Janssen-partnered investigational gene therapies for the treatment of inherited retinal diseases:

  • In 2019, MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered into a worldwide collaboration and license agreement to develop, manufacture and commercialize gene therapies for inherited retinal diseases, including MeiraGTx’s ongoing Phase 1/2 studies of AAV-RPGR for X-linked retinitis pigmentosa (XLRP) and AAV-CNGB3 and AAV-CNGA3 for achromatopsia (ACHM).
  • In the first quarter of 2020, the European Medicines Agency (EMA) granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations to AAV-RPGR. PRIME designation was granted based on clinical data from the ongoing Phase 1/2 trial. To be awarded PRIME, a medicine must demonstrate potential to benefit patients with unmet medical needs based on early clinical data. MeiraGTx expects to engage with global regulatory authorities in 2020 with the goal of optimizing and accelerating the development of AAV-RPGR.
  • MeiraGTx expects to report data from the ongoing clinical trial of AAV-RPGR in 2020.
  • MeiraGTx continues to advance the Company’s ongoing Phase 1/2 studies of AAV-CNGB3 and AAV-CNGA3 for the treatment of ACHM associated with mutations in the CNGB3 and CNGA3 genes.

AAV-GAD for the treatment of Parkinson’s Disease:

  • MeiraGTx anticipates that the Company will file an Investigational New Drug application (IND) in the second half of 2020.

AAV-RPE65 for the treatment of RPE65­-Associated Retinal Dystrophy:

  • In 2019, MeiraGTx presented data from a Phase 1/2 clinical trial which demonstrated that, in addition to meeting its primary endpoint of safety, AAV-RPE65 demonstrated statistically significant improvement across several assessments of visual function. MeiraGTx expects to meet with global regulatory authorities in 2020 to determine the regulatory pathway for AAV-RPE65.

For more information related to our clinical trials, please visit

Recent Corporate Development Highlights and Anticipated 2020 Milestones

Second Viral Vector Manufacturing Facility and Plasmid Production Facility

  • MeiraGTx has completed feasibility studies for a second cGMP viral vector manufacturing facility and a cGMP plasmid production facility.
  • The Company anticipates that its plasmid production facility will be operational by the end of 2020 and expects to initiate construction of its viral vector facility in mid-2020.

Expanding Clinical, Regulatory, Manufacturing, MSAT and Preclinical Development Teams

  • MeiraGTx continues to substantially increase key personnel across functional areas to support the Company’s broad pipeline of optimized investigational gene therapies. The MeiraGTx team now includes more than 155 full-time employees.    

Financial Results

Cash and cash equivalents were $227.4 million as of December 31, 2019, compared to $68.1 million as of December 31, 2018.

Research and development expenses were $24.9 million for the year ended December 31, 2019, compared to $33.6 million for the year ended December 31, 2018. The decrease of $8.7 million was primarily due to research funding provided to us under the Janssen collaboration agreements in the amount of $27.9 million and an increase in the research and development credit in the United Kingdom of $8.6 million. These were partially offset by increases in costs related to our ocular and xerostomia clinical trials, clinical trial material manufacturing, restructuring of certain licenses, payroll, share-based compensation and rent.  

General and administrative expenses were $46.7 million for the year ended December 31, 2019, compared to $44.5 million for the year ended December 31, 2018. The increase of $2.2 million was primarily due to increases in legal fees, rent, insurance, consulting fees, travel expenses, director fees and other general and administrative expenses, which was partially offset by decreases in share-based compensation and payroll.

Foreign currency gain was $3.2 million for the year ended December 31, 2019 compared to a loss of $3.8 million for the year ended December 31, 2018. The change of $7.6 million was primarily due to a strengthening of the pound sterling against the U.S. dollar in 2019.

Net loss attributable to ordinary shareholders for the year ended December 31, 2019 was $54.8 million, or $1.65 basic and diluted net loss per ordinary share, compared to a net loss attributable to ordinary shareholders of $84.7 million, or $4.47 basic and diluted net loss per ordinary share for the year ended December 31, 2018.  

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated 2020 milestones regarding our pre-clinical and clinical data and reporting of such data and the timing of results of data, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials or other manufacturing issues; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; changes in tax policy or treatment; our ability to utilize our loss and tax credit carryforwards; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.


Elizabeth Broder
(646) 860-7983


W2O pure
Christiana Pascale
(212) 267-6722


    For the Year Ended December 31
    2019    2018 
License revenue - related party   $  13,291,956     $  —  
Operating expenses:            
General and administrative   $  46,684,297     $  44,483,938  
Research and development      24,875,659        33,620,223  
Total operating expenses      71,559,956        78,104,161  
Loss from operations      (58,268,000 )      (78,104,161 )
Other non-operating income (expense):            
Foreign currency gain (loss)      3,199,774        (3,824,383 )
Change in fair value of warrant liability      —        (1,514,775 )
Other income      —        83,075  
Interest income      370,603        53,408  
Interest expense      (48,612 )      (33,429 )
Loss before income taxes      (54,746,235 )      (83,340,265 )
Benefit for income taxes      —        474,391  
Net loss      (54,746,235 )      (82,865,874 )
Other comprehensive (loss) income:            
Foreign currency translation, net of tax of $0 and $474,391 in 2019 and 2018, respectively      (2,087,708 )      2,316,143  
Total comprehensive loss   $  (56,833,943 )   $  (80,549,731 )
Net loss   $  (54,746,235 )   $  (82,865,874 )
Accretion on convertible preferred C shares and warrants      —        (1,806,512 )
Net loss attributable to ordinary shareholders   $  (54,746,235 )   $  (84,672,386 )
Basic and diluted adjusted net loss per ordinary share   $  (1.65 )   $  (4.47 )
Weighted-average number of ordinary shares outstanding      33,161,860        18,948,520  


    December 31   December 31
    2019    2018 
CURRENT ASSETS:            
Cash and cash equivalents   $  227,233,384     $  68,080,175  
Accounts receivable - related party      23,337,377        —  
Prepaid expenses      4,464,085        1,937,785  
Tax incentive receivable      11,974,437        3,416,932  
Other current assets      1,970,585        1,217,173  
Total Current Assets      268,979,868        74,652,065  
Property and equipment, net      23,858,108        22,014,237  
Security deposits      951,138        105,085  
In-process research and development      777,655        —  
Restricted cash      123,376        123,376  
Other assets      195,053        —  
Right-of-use assets      29,002,448        —  
TOTAL ASSETS   $  323,887,646     $  96,894,763  
Accounts payable   $  3,759,339     $  3,042,861  
Accrued expenses      18,083,757        11,991,697  
Lease obligations, current      1,674,210        27,199  
Deferred revenue - related party, current      25,678,515        —  
Other current liabilities      —        437,053  
Total Current Liabilities      49,195,821        15,498,810  
Deferred revenue - related party      60,535,576        —  
Lease obligations      21,504,340        7,097  
Asset retirement obligations      1,654,755        128,119  
Deferred rent      —        201,264  
Deferred income tax liability      195,053        —  
TOTAL LIABILITIES      133,085,545        15,835,290  
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized
36,791,906 issued and outstanding at December 31, 2019
27,386,632 issued and outstanding at December 31, 2018
     1,429        1,064  
Capital in excess of par value      395,630,666        229,054,460  
Accumulated other comprehensive (loss) income      (1,794,042 )      293,666  
Accumulated deficit      (203,035,952 )      (148,289,717 )
Total Shareholders' Equity      190,802,101        81,059,473  
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY   $  323,887,646     $  96,894,763  

MGX logo.png

Source: MeiraGTx